OBJECTIVES: Understanding the heterogeneous characteristics of Multiple sclerosis (MS) patients is not properly studied in the past. The objective of this study is to assess the characteristics of geriatric patients diagnosed with MS and taking disease modifying therapies (DMTs) in the US.  METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with MS and were prescribed DMTs between January 2010 to December 2012 were included in the study. All patients were ≥ 65 years of age and continuously enrolled in the same health plan for at least a year. Descriptive statistics and chi-square tests were performed on the data and statistical significance level was set a priori at 0.05. RESULTS: There were a total of 88,921 patients that met the study inclusion criteria. Of these, 67,335 (75.7%) were females, mean age was 68.2±3.4years, and majority of the patients were between 65 and 75 years of age (95.4%). Thirty five percentage of the patients were from Midwest, 31.6% were from East, 22% from south and 11.4% from West of the USA. Majority (66.9%) of the patients was taking subcutaneous injections, 31.2% were taking IV/IM and 1.9% was taking oral DMTs (p<0.001). 48.8% of the patients was under a group coverage, 58.8% of the patients were taking a DMT that was under their health plan formulary with a significant variation between the groups (p<0.001). The mean number of days of DMT supply was 33.3±16.1 with a significant difference between the three groups (p<0.001). Females enrolled continuously 5.5 ± 3.4 years with mean total number claims of 637.1±504.7 during the study period.  CONCLUSIONS: Majority of the patients taking DMTs was females and was between 65 and 75 years of age. Most of the patients were taking subcutaneous injections compared to other forms of DMTs.